Skip to main content
GNMSF logo

Genmab A/S (GNMSF) Stock Price & Analysis

Genmab A/S (GNMSF) — price $521.80 (+1.32%), as of the Nov 19, 2026 trading session; market cap $32.2B.

Educational signal · not a buy or sell recommendation · How to read this

$521.80 +$6.80 (+1.32%) Market Cap $32.2B

Genmab A/S · GNMSF · Healthcare · Biotechnology

Genmab A/S, founded in 1999 and based in Copenhagen, Denmark, is a biopharmaceutical firm focused on developing antibody-based therapeutics to treat cancer and a range of other diseases.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RPRX · Royalty Pharma plc · 73 /100
  • UTHR · United Therapeutics Corporation · 97 /100
  • INCY · Incyte Corporation · 91 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$521.80
Change on the day+1.32%
52-week range$232.34–$581.00
Market capitalisation$32.2B—
Price / earnings (trailing)43.33
Shares traded on the day2
Beta (volatility vs the S&P 500)0.66

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $249, high $564, latest $522. $564 $249 high $564 Oct 17, 2025 Nov 19, 2026 · $522 $332Oct 17, 2025$283Oct 31, 2025$304Nov 14, 2025$326Nov 28, 2025$317Dec 12, 2025$333Dec 26, 2025$340Jan 9, 2026$327Jan 23, 2026$331Feb 6, 2026$284Feb 20, 2026$290Mar 6, 2026$275Mar 20, 2026$265Apr 2, 2026$282Apr 17, 2026$265May 1, 2026$265May 15, 2026$252May 29, 2026$249Jun 12, 2026$262Jun 26, 2026$276Jul 10, 2026$275Jul 24, 2026$312Aug 7, 2026$337Aug 21, 2026$329Sep 4, 2026$343Sep 18, 2026$355Oct 2, 2026$367Oct 16, 2026$564Oct 30, 2026$510Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Genmab A/S (GNMSF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Unfavorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Negative
Debt/Equity Weak
ROE Moderate
Gross Margin Strong

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Genmab A/S (GNMSF), and what does it report?

Short answer

Genmab A/S, founded in 1999 and based in Copenhagen, Denmark, is a biopharmaceutical firm focused on developing antibody-based therapeutics to treat cancer and a range of other diseases. Genmab A/S (GNMSF) is classified as Healthcare / Biotechnology. SEC filing business address: Toldbodgade 33, 1253 Copenhagen K, G7, 00000. It employs 3,029 people and is led by Jan van de Winkel. In Q3 FY2026 it reported revenue of $1.19B and net income of $342M. The market values it at $32.2B.

2 · Latest results

What do the latest results show for Genmab A/S (GNMSF)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $1.19B. Against analyst estimates the company has EPS beat 6 of the last 8 reports.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$1.19B$342M$5.51 (diluted)
Q2 FY2026$1.13B$297M$4.81 (diluted)
Q1 FY2026$896M$53M$0.83 (diluted)
Q4 FY2025$1.06B$31M$0.46 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Genmab A/S (GNMSF)?

Short answer · as of

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway. The distress and quality screens read Altman Z 20.96 · Piotroski F 5. Trailing ratios: ROE 12.1% · ROA 8.2% · current ratio 2.45.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held GNMSF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported GNMSF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What Investors Ask About Genmab A/S (GNMSF) — Healthcare

These answers are editorial: 1 of these 8 answers is drawn from the GNMSF research dossier (written Mar 15, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is GNMSF a good stock to buy?

Stock Expert AI does not rate GNMSF buy, sell or hold. Genmab A/S has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the GNMSF stock price today?

The last price recorded for Genmab A/S (GNMSF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What does Genmab A/S do?

Genmab A/S is a biotechnology company focused on the creation and development of antibody therapeutics for the treatment of cancer and other diseases.

What are the key factors to evaluate for GNMSF?

Evaluate GNMSF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. The drug is currently under review by regulatory agencies. Not financial advice.

How frequently does GNMSF data refresh on this page?

GNMSF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven GNMSF's recent stock price performance?

Genmab A/S (GNMSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative antibody therapeutics platform. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider GNMSF overvalued or undervalued right now?

The trailing P/E of Genmab A/S (GNMSF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research GNMSF before investing?

Before investing in Genmab A/S (GNMSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 20 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.